Athira Pharma Inc at JMP Securities Life Sciences Conference Transcript
[Thank you, everybody], for joining us this morning at the JMP Securities Life Science Conference. Excited to be joined next by Athira Pharma with Mark Litton, the company's CEO; and Hans Moebius, the company's Chief Medical Officer.
Thank you, Hans and Mark, for being here, another exciting year for Athira. You're focused on a novel class of drugs for broadly neurodegenerative diseases. I guess, with that, I'll turn it over to you, Mark, just to give a quick overview of the company, and we'll go from there.
Great. Thank you, Jason, for inviting us. Thank you all for coming to hear our chat. For those of you who don't know us, Athira is a late-stage biotech company. We're focused completely on neurodegeneration. We've spent many, many years identifying small molecules that enhance a natural repair mechanism or the HGF/MET system.
And HGF/MET has been known for decades. Really, it's very important for neuronal health, neuroprotection,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
